UnknownNot Applicable

Korean Cohort Study of AKI & HRS in Cirrhosis

South Korea245 participantsStarted 2017-08-01

Plain-language summary

The aim of this study is to investigate i) whether two biomarkers (urine NAG, urinary cystatin C) could be predictive factor in patient with liver cirrhosis, , and ii) whether these biomarkers can predict response of terlipressin.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with liver cirrhosis diagnosed as acute kidney injury or hepatorenal syndrome * Patients who voluntarily agreed to the study Exclusion Criteria: * Patients with active bleeding (eg, varix bleeding) within 7 days * Patients with hepatocellular carcinoma * Patients with hypersensitivity to terlipressin * Patients with anuria * Pregnant and lactating patients * Patients who did not agree with the study

What they're measuring

Overall survival

Timeframe: up to 3 years

Trial details

NCT IDNCT03530761

SponsorSoonchunhyang University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-31

Contact for this trial

Jeong-Ju Yoo, Doctor

82-10-9676-3128 puby17@naver.com

View on ClinicalTrials.gov More Liver Cirrhosis trials